|
- ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion
- Enjaymo: Uses, Dosage, Side Effects Warnings - Drugs. com
Enjaymo (sutimlimab-jome) is used in the treatment cold agglutinin disease (CAD) Includes Enjaymo side effects, interactions and indications
- Sutimlimab - Wikipedia
Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD) [1][3][4] It is given by intravenous infusion [1] Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro [5] The most common side effects include headache, high blood pressure, urinary tract infection (infection of the
- LABEL - accessdata. fda. gov
ENJAYMO solution is a clear to slightly opalescent and colorless to slightly yellow liquid Do not administer if discolored or if other foreign particulate matter is present Withdraw the calculated volume of ENJAYMO from the appropriate number of vials based on the recommended dosage (see Table 1) and add to an empty infusion bag
- ENJAYMO® (sutimlimab-jome) | Healthcare Professional Website
ENJAYMO, a proximal classical complement C1s inhibitor, increases susceptibility to serious infections, including those caused by encapsulated bacteria e g Neisseria meningitidis (any serogroup, including non-groupable strains), Streptococcus pneumoniae, and Haemophilus influenzae type B
- Enjaymo - European Medicines Agency (EMA)
Overview Enjaymo is a medicine for treating haemolytic anaemia (excess breakdown of red blood cells) in adults with cold agglutinin disease (CAD) CAD is a rare blood disorder where the immune system (the body’s natural defence) recognises red blood cells as foreign and attacks them This causes agglutination (clumping together) and haemolysis (disruption) of the red blood cells, resulting
- DailyMed - ENJAYMO- sutimlimab-jome injection, solution . . .
ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients [see Warnings and Precautions (5 2) and Adverse Reactions (6 1)]
- Enjaymo (sutimlimab): Uses, Side Effects, Dosage Reviews
Enjaymo (sutimlimab or sutimlimab-jome) is a newly-approved medication used to lower the need for blood transfusions in adults with a rare form of anemia called cold agglutinin disease (CAD) It's given as an infusion into the veins by a healthcare provider
|
|
|